In the pipeline
Our pipeline is focused on research in therapeutic areas where we can accelerate the development of transformational, life-changing medicines for patients
- X
Our pipeline at a glance
As of February 06, 2025
50
Compounds in development
40+
Disease areas being studied
Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.
In the pipeline
Filter
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
Brand Name / Compound
Research Area / Line of Therapy
Phase 1 P 1
Phase 2 P 2
Phase 3 P 3
{"categoryColor":"#595454","phase":[{"name":"1 - Phase I","value":"bms:phase/phase-1","desc":"1"},{"name":"2 - Phase II","value":"bms:phase/phase-2","desc":"2"},{"name":"3 - Phase III","value":"bms:phase/phase-3","desc":"3"}],"listings":[{"compoundname":"<p><b>iza-bren (EGFRxHER3 ADC)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors *<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b><a href='/content/dam/packageinserts/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L NSCLC PD-L1≥50%<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b><a href='/content/dam/packageinserts/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>1L NSCLC PD-L1<50%<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='' aria-label=''><b>OPDIVO<\/b><\/a><sup>®<\/sup><br />\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Adjuvant Hepatocellular Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='' aria-label=''><b>OPDIVO<\/b><\/a><sup>®<\/sup><br />\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Peri-adjuvant Muscle-Invasive Urothelial Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/bladder"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_opdualag.pdf' title='' class='' target='_blank' aria-label=''>Opdualag<\/a> <sup>TM<\/sup> (nivolumab and relatlimab-rmbw)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Adjuvant Stage III/IV Melanoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/melanoma"},{"compoundname":"<p><b>iberdomide<\/b><br />\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>iberdomide<\/b><br />\r\n<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Post-Autologous Stem Cell Transplant Maintenance Newly Diagnosed Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>mezigdomide<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ Multiple Myeloma Vd<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>mezigdomide<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2L+ Multiple Myeloma Kd<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''>REBLOZYL<\/a><\/b><sup>®<\/sup> <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L Non-Transfusion Dependent Myelodysplastic Syndrome-Associated Anemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelodysplastic-syndromes"},{"compoundname":"<p><b><a href='http://packageinserts.bms.com/pi/pi_breyanzi.pdf' title='' class='' target='_blank' aria-label=''>BREYANZI<\/a><sup>®<\/sup> (lisocabtagene maraleucel)<\/b><br>\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Relapsed/Refractory Marginal Zone Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>golcadomide<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦High Risk 1L Large B-cell Lymphoma<\/p>\r\n<p> <\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>golcadomide<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Relapsed/Refractory Follicular Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''>REBLOZYL<\/a><\/b><sup>®<\/sup> <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L Transfusion Dependent Myelofibrosis-Associated Anemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelofibrosis"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Sjögren's Syndrome<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Psoriatic Arthritis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Discoid Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BMS-986322 (TYK2 Inhibitor)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Moderate-to-Severe Psoriasis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>afimetoran<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>admilparant<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦Idiopathic Pulmonary Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>admilparant<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Progressive Pulmonary Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>IL2-CD25<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>AR LDD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦Metastatic Castration-Resistant Prostate Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/prostate"},{"compoundname":"<p><b>FAAH/MGLL Dual Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Multiple Sclerosis Spasticity<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>FAAH/MGLL Dual Inhibitor<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Alzheimer's Disease Agitation<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>arlo-cel (GPRC5D CAR T)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2-4L Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>arlo-cel (GPRC5D CAR T)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Relapsed/Refractory Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_camzyos.pdf' title='' class='' target='_blank' aria-label=''>CAMZYOS<\/a>® (mavacamten)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Non-Obstructive Hypertrophic Cardiomyopathy<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>MYK-224<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Heart Failure with Preserved Ejection Fraction<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>Anti-CCR8<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>CK1α Degrader<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Hematologic Malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/hematologic-malignancies"},{"compoundname":"<p><b>Anti-MTBR Tau<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>eIF2B Activator<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='' aria-label=''>OPDIVO<\/a><sup>®<\/sup>(nivolumab) +<a href='http://packageinserts.bms.com/pi/pi_yervoy.pdf' title='' class='' target='' aria-label=''>YERVOY<\/a><sup>®<\/sup>(ipilimumab)<a href='http://packageinserts.bms.com/pi/pi_yervoy.pdf' title='' class='' target='' aria-label=''><\/a><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L Hepatocellular Carcinoma (Registration)<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":"<p><b>PKCθ Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p><b>✦<\/b>Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>subcutaneous nivolumab + relatlimab + rHuPH20<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L Melanoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/melanoma"},{"compoundname":"<p><b>milvexian<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Acute Coronary Syndrome<b><sup>*<\/sup><\/b><\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>milvexian<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Atrial Fibrillation<sup>*<\/sup><\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>milvexian<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Secondary Stroke Prevention<sup>*<\/sup><\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Severe Refractory Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Autoimmune Diseases<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>HELIOS CELMoD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>obexelimab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦IgG4-Related Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BCL6 LDD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>BMS-986454<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BMS-986460<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Prostate Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/prostate"},{"compoundname":"<p><b>CD33-GSPT1 ADC<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Acute Myeloid Leukemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/acute-myeloid-leukemia"},{"compoundname":"<p><b>Dual Targeting BCMAxGPRC5D CAR T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Relapsed/Refractory Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2L Colorectal Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/colorectal"},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Multiple Sclerosis<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Myasthenia Gravis<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ SSTR2+ Gastroenteropancreatic Neuroendocrine Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>SOS1 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Extensive Stage SCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''>COBENFY<\/a><sup>TM<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Adjunctive Schizophrenia<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''>COBENFY<\/a><sup>TM<\/sup><\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Psychosis in Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>TRPC4/5 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Mood and Anxiety Disorders<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='' aria-label=''>REBLOZYL<\/a><\/b>® <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>A-Thalassemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/a-thalessemia"},{"compoundname":"<p><b>BMS-986495<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Neurodegenerative Diseases<b><sup>*<\/sup><\/b><\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>BMS-986463<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>HbF Activating CELMoD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Sickle Cell Disease<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/sickle-cell-disease"},{"compoundname":"<p><b>nivolumab+relatlimab HD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L NSCLC PD-L1≥1%<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>BMS-986484<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>RYZ801<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Hepatocellular Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":"<p><b>atigotatug (Anti-Fucosyl GM1) + nivolumab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L Extensive Stage SCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>HR+/HER2- Unresectable Metastatic Breast Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/breast"},{"compoundname":"<p><b>iza-bren (EGFRxHER3 ADC)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦1L NSCLC *<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>iza-bren (EGFRxHER3 ADC)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Metastatic NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>BMS-986490<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>BMS-986488<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>BMS-986482<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"}],"therapeuticarea":[{"color":"#dbc5c5","name":"bms:therapeutiic-area/cardiovascular","value":"Cardiovascular"},{"color":"#fedcca","name":"bms:therapeutiic-area/hematology","list":[{"name":"bms:tumor/a-thalessemia","value":"A-Thalessemia"},{"name":"bms:tumor/acute-myeloid-leukemia","value":"Acute Myeloid Leukemia (AML)"},{"name":"bms:tumor/hematologic-malignancies","value":"Hematologic Malignancies"},{"name":"bms:tumor/lymphoma","value":"Lymphoma"},{"name":"bms:tumor/multiple-myeloma","value":"Multiple Myeloma (MM)"},{"name":"bms:tumor/myelodysplastic-syndromes","value":"Myelodysplastic Syndromes (MDS)"},{"name":"bms:tumor/myelofibrosis","value":"Myelofibrosis (MF)"},{"name":"bms:tumor/sickle-cell-disease","value":"Sickle Cell Disease"}],"value":"Hematology"},{"color":"#c5ffe6","name":"bms:therapeutiic-area/immunology","value":"Immunology"},{"color":"#d8ddd1","name":"bms:therapeutiic-area/neuroscience","value":"Neuroscience"},{"color":"#c0f2fb","name":"bms:therapeutiic-area/oncology","list":[{"name":"bms:tumor/bladder","value":"Bladder"},{"name":"bms:tumor/breast","value":"Breast"},{"name":"bms:tumor/colorectal","value":"Colorectal"},{"name":"bms:tumor/hepatocellular-carcinoma","value":"Hepatocellular Carcinoma (HCC)"},{"name":"bms:tumor/lung","value":"Lung"},{"name":"bms:tumor/melanoma","value":"Melanoma"},{"name":"bms:tumor/prostate","value":"Prostate"},{"name":"bms:tumor/solid-tumors","value":"Solid Tumors"}],"value":"Oncology"}],"subCategoryColor":"#A69F9F"}
Please click on product name to see the Full U.S. Prescribing Information for KRAZATI®, OPDIVO®, OPDUALAG™, REBLOZYL®, BREYANZI®, SOTYKTU™, and COBENFY™ including Boxed WARNINGS for BREYANZI®.
Development Partnership: Anti-CCR8 + nivolumab, nivolumab + relatlimab HD, OPDIVO, OPDUALAG, YERVOY: Ono; AUGTYRO, COBENFY, KRAZATI: Zai Lab; BMS-986495: Prothena; iza-bren (EGFRxHER3 ADC): SystImmune; milvexian: Johnson & Johnson; obexelimab: Zenas BioPharma; PKCθ Inhibitor: Exscientia; REBLOZYL: Merck; rHuPH20: Halozyme
* Partner-run study
✦ NME Lead Indication
NSCLC = Non-Small Cell Lung Cancer
SCLC = Small Cell Lung Cancer
ADC = Antibody Drug Conjugate
For information on approved uses, refer to approved product labeling. Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study. Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.